ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Clinical trials for ER-POSITIVE, HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-POSITIVE, HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-POSITIVE, HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill could outsmart resistant breast cancer
Disease control OngoingThis study is for people with a type of advanced breast cancer (HR+/HER2-) that has a specific gene change (ESR1 mutation) but hasn't gotten worse on current treatment. It compares switching to a new oral drug (AZD9833) plus a CDK4/6 inhibitor versus staying on standard therapy (…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New hope for advanced breast cancer: early safety trial underway
Disease control OngoingThis early-phase study tests the safety and tolerability of a new drug, HRS8807, given alone or with another drug (SHR6390) in people with ER-positive, HER2-negative breast cancer that has spread or is locally advanced. The trial enrolls 46 adults who have already tried at least …
Matched conditions: ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New oral drug combo aims to outperform standard therapy in advanced breast cancer
Disease control OngoingThis study tests whether a new oral drug (camizestrant) combined with palbociclib works better than the standard anastrozole plus palbociclib for people with ER-positive, HER2-negative advanced breast cancer that has spread or returned after prior treatment. About 1,370 participa…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 08, 2026 13:09 UTC
-
AI may predict breast cancer return better than current methods
Knowledge-focused OngoingThis study looks at whether an artificial intelligence (AI) program can accurately predict if early-stage breast cancer will come back in a different part of the body. Researchers will analyze tissue samples and health records from 2,200 women who were previously treated for ER-p…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
Sponsor: Spotlight Medical • Aim: Knowledge-focused
Last updated Jun 01, 2026 17:55 UTC